Anixa Biosciences, акция обыкновенная (US03528H1095, ANIX, CY71, ANIX.P)

By using the body's immune system, Anixa Biosciences, Inc. (former ITUS Corporation) is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.

• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Чистый долг / EBITDA
• Общий долг / Капитал
• Выручка
• Рентабельность по EBITDA (%)